Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cholesterol-Lowering Drugs and Steroid Hormones, Bile Acids, Vitamin D, Immune System, and Related Diseases
2024-516967-10-00Phase 4Authorised
- Sponsor
- Medical University of Vienna
- Start
- Dec 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of alirocumab, evolocumab, inclisiran, rosuvastatin and atorvastatin in hyperlipidemia (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Changes in sex steroid levels. Planned start Dec 2024; status: authorised.
02
Drugs
alirocumabevolocumabinclisiranrosuvastatinatorvastatin
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on 2024-516967-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516967-10-00.